References
- Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509.
- Lipsky JL. Mycophenolate mofetil. Lancet. 1996;348:1357–1359.
- Davison SC, Morris-Jones R, Powles AV, Fry L. Change of treatment from cyclosporine to mycophenolate mofetil in severe psoriasis. Br J Dermatol. 2000;14:405–407.
- Kreuter A, Tomi NS, Weiner SM, Huger M, Altmeyer P, Gambichler T. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol. 2007;15:1321–1327.
- Geilen CC, Arnold M, Orfanos CE. Mycophenolate mofetil as a systemic antipsoriatic agent:positive experience in 11 patients. Br J Dermatol. 2001;144:583–586.
- Budde K, Glander P, Diekmann F, Waiser J, Fritsche L, Dragun D, et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother. 2004;5:1333–1345.
- Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157:238–244.
- Pedraz J, Daudén E, Delgado-Jiménez Y, García-Río I, García-Díez A. Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporine. J Eur Acad Dermatol Venereol. 2006;20:702–706.
- Geilen CC, Tebbe B, García-Bartels C, Krengel S, Orfanos CE. Successful treatment of erythrodermic psoriasis with mycophenolate mofetil. Br J Dermatol. 1998;138:1101–1122.
- Haufs MG, Beissert S, Grabbe S, Schutte B, Luger TA. Psoriasis vulgaris treated successfully with mycophenolate mofetil. Br J Dermatol. 1998;138:179–181.
- Tong DW, Walder BK. Widespread plaque psoriasis responsive to mycophenolate mofetil. Australas J Dermatol. 1999;40:135–137.
- Nousari HC, Sragovich A, Kimyai-Asadi A, Orlinsky D, Anhalt GJ. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol. 1999;40:265–268.
- Grundmann-Kollmann M, Mooser G, Schraeder P, Zollner T, Kaskel P, Ochsendorf F, et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol. 2000;42:835–837.
- Dauden E, Sánchez-Peinado C, Ruiz-Genao D García-F-Villalta M, Onate MJ, García-Díez A. Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis. Br J Dermatol. 2004;150:132–135.
- Sanford M, Keating GM. Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejection. Drugs. 2008;68:2505–2533.
- Darji P, Vijayaraghavan R, Thiagarajan CM, Sharma RK, Subbarao B, Pishardy R, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders. Transplant Proc. 2008;40:2262–2267.
- Zhou Y, Rosenthal D, Dutz J, Ho V. Mycophenolate mofetil (CellCept) for psoriasis: a two-center, prospective, open-label clinical trial. J Cutan Med Surg. 2003;7:193–197.
- Orvis AK, Wesson SK, Breza TS Jr, Church AA, Mitchell CL, Watkins SW. Mycophenolate mofetil in dermatology. J Am Acad Dermatol. 2009;60:183–199.
- Jackson JM, Fowler JF Jr, Callen JP, Lorenz DJ. Mycophenolate mofetil for the treatment of chronic dermatitis: an open-label study of 16 patients. J Drugs Dermatol. 2010;9:356–362.
- van Velsen SG, Haeck IM, Bruijnzeel-Koomen CA, de Bruin-Weller MS. First experience with enteric-coated mycophenolate sodium (Myfortic(R)) in severe recalcitrant adult atopic dermatitis: an open label study. Br J Dermatol. 2009;160:687–691.